Clinical Trials Logo

Filter by:
NCT ID: NCT06435910 Recruiting - Clinical trials for Multiple Myeloma or Plasmacytoma

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Start date: May 11, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

NCT ID: NCT06435897 Recruiting - Autoimmune Diseases Clinical Trials

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Start date: May 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the feasibility, safety and efficacy of mesenchymal stem cells (MSCs) in combination with CAR-T cells in treating autoimmune disease. Another goal of the study is to learn more about the safety and function of the MSCs combined with CAR-T cells and their long term effects in autoimmune disease patients.

NCT ID: NCT06435767 Recruiting - Chemotherapy Effect Clinical Trials

Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant Chemotherapy

Start date: January 1, 2024
Phase:
Study type: Observational

Ampullary cancer, a rare malignancy, lacks standardized guidelines for effective multimodal treatment following curative resection. The opinions on whether postoperative chemotherapy can improve the long-term survival of ampullary adenocarcinoma (AA) are discordant. This aspect remains poorly studied, with comparably scant research conducted on it. log odds of positive lymph nodes (LODDS), a quantitative variable, can continuously and accurately reflect the burden of nodal involvement, which suggested a potential ability to identify AA patients benefiting from postoperative adjuvant chemotherapy (ACT). Therefore, Mainly focused issues of ACT addressed in the study are as follows: 1) the role of ACT in improving long-term survival for patients with AA after curative resection. 2) the role of LODDS in identifying postoperative AA patients benefiting from ACT. 3) compared with T and N classifications reported previously, the advantage of LODDS in identifying ACT-benefited patients. In this cohort study, a large scale of sample size was conducted by drawing on the collective experience of the National Cancer Center of China. The patients treated with radiotherapy were excluded to concentrate on the effect of ACT.

NCT ID: NCT06435728 Active, not recruiting - Prognosis Clinical Trials

Predictive Value of Combining AccuIMR and AccuFFR in Patients With STEMI

Start date: March 1, 2024
Phase:
Study type: Observational

Patients with acute myocardial infarction were enrolled retrospectively. The fractional flow reserve (AccuFFR) and microcirculatory resistance index (AccuIMR) based on coronary angiography were analyzed, and the relationship between FFR and IMR and the prognosis of patients with acute myocardial infarction was analyzed

NCT ID: NCT06435702 Not yet recruiting - Prostate Cancer Clinical Trials

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Start date: June 1, 2024
Phase:
Study type: Observational

This study is an open, prospective, single-center observational clinical study to evaluate the efficacy and safety of immediate adjuvant ADT with darotarolimide in the treatment of patients with positive lymph nodes after radical prostatectomy for prostate cancer.

NCT ID: NCT06435676 Recruiting - Clinical trials for Overweight or Obesity; Type 2 Diabetes

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Start date: June 4, 2024
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.

NCT ID: NCT06435260 Not yet recruiting - Pancreatic Cancer Clinical Trials

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of locally advanced pancreatic cancer.

NCT ID: NCT06435195 Recruiting - Pituitary Diseases Clinical Trials

Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases

Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. The main questions it aims to answer are: - What are the influencing factors and rates of remission? - What are the comorbidities associated with these diseases? - What are the perioperative events, radiological findings, and pathological features? Researchers will compare different patient groups to see if there are significant differences in these outcomes. Participants will: - Undergo detailed clinical evaluations. - Provide medical history and data for analysis. - Participate in follow-up assessments to monitor disease progression and treatment outcomes.

NCT ID: NCT06435182 Completed - Dry Eye Clinical Trials

Study of OT202 in Treating Moderate to Severe Dry Eye

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.

NCT ID: NCT06435104 Not yet recruiting - Early Breast Cancer Clinical Trials

Aromatherapy in the Treatment of Early Breast Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect. However, it is worth noting that anxiety caused by breast cancer itself and adverse reactions of chemotherapy not only affects the patients' quality of life, but also reduces the treatment compliance and even survival benefits of patients. Previous literatures have shown that aromatherapy may improve chemotherapy-induced anxiety and even affect anti-tumor immunity. Therefore,we envisage that aromatherapy conbimed with chemotherapy in the treatment of breast cancer in clinical practice has the advantages of improving efficacy and survival. However, there is still a lack of relevant clinical studies. We planned to design a prospective clinical trial to evaluate the efficacy and safety of aromatherapy combined with chemotherapy on anxiety, relevant sympathetic neurotransmitters and tumor immunity in breast cancer patients.